Sutro Biopharma, Inc. STRO
8.72 USD +0.22 (+2.59%)
As ofNov 19, 2026, 3:41 PM EST
8.48 Day range 8.98
7.15 52-week range 43.85
- YTD
- -24.63%
- 1 year
- -4.18%
News
benzinga.com Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57 Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.
benzinga.com Sutro Biopharma Q3 EPS $(1.90) Beats $(1.91) Estimate, Sales $9.100M Miss $10.342M Estimate Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(1.91) by 0.52 percent. This is a 71.64 percent increase over losses of…
globenewswire.com Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights – STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –benzinga.com Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first…
